Drug intelligence / Profile preview

viral macrophage-inflammatory protein

Development stage
Preclinical
Modality
Recombinant Proteins and Enzymes, Peptides
01

Overview

Viral Macrophage-Inflammatory Protein (vMIP) refers to a family of chemokine analogs encoded by human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus). The two main forms are vMIP-I and vMIP-II. These proteins mimic host chemokines and modulate the immune response to benefit the virus. - **vMIP-II** is a highly basic 71-residue monomeric protein that binds a broad spectrum of chemokine receptors. It acts as an antagonist at CCR1, CCR2, CCR5, and CXCR4; as an agonist at CCR3 and CCR8; and can block HIV cell entry via antagonism at CCR5/CXCR4. It preferentially inhibits Th1-type inflammation while upregulating Th2 responses[6][7][2]. - **vMIP-I** selectively activates CC chemokine receptor 8 (CCR8), for which CCL1 is the endogenous ligand[8]. Both proteins help the virus evade host immunity by interfering with leukocyte trafficking and adaptive immune responses.

Other names
viral macrophage inflammatory protein-Iviral macrophage inflammatory protein-II
02

Targets

CXCR4 (C-X-C motif chemokine receptor 4)CCR8CCR1CCR3 (C-C chemokine receptor type 3)CCR5 (C-C chemokine receptor type 5)

Beyond the preview

Go deeper on viral macrophage-inflammatory protein.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on viral macrophage-inflammatory protein.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call